Immediate Impact

38 standout
Sub-graph 1 of 14

Citing Papers

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
2024 Standout
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
2 intermediate papers

Works of Fengdan Wang being referenced

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy
2018

Author Peers

Author Last Decade Papers Cites
Fengdan Wang 40 51 53 83 57 38 284
Iwona Kucybała 73 62 33 38 22 21 299
Olga Růžičková 14 92 27 66 51 24 300
Eckhart Fröhlich 73 12 25 111 41 32 311
Kevin Yuqi Wang 38 36 16 44 19 28 286
Prashant Kumar Verma 19 10 37 53 40 42 324
Yining Wang 34 21 21 89 40 36 217
Natalia Shor 45 49 37 29 12 38 313
Marius Horger 22 15 22 52 23 23 204
N. Faye 91 45 17 85 33 23 269
B. Kurtz 96 114 15 59 35 33 334

All Works

Loading papers...

Rankless by CCL
2026